stockrow
Friday 6 November 2026
Export RYTM’s income statement to Excel — free account
Rhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
112.38
7.36
+7.01%
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Total debt
Rhythm Pharmaceuticals, Inc.'s total debt at the end of fiscal 2022 was $77.8M, up 2,948.0% from $2.6M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $106.1M. Rhythm Pharmaceuticals, Inc. ranks 82nd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $77.8M | 2,947.98% |
| FY2021 | $2.6M | (17.34%) |
| FY2020 | $3.1M | (13.27%) |
| FY2019 | $3.6M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $106.1M | 31.10% |
| Jun 2023 | $81.0M | 2.09% |
| Mar 2023 | $79.3M | 1.99% |
| Dec 2022 | $77.8M | 3,595.53% |
| 15 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. compare | $1.4B |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $864.1M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| AXSM Axsome Therapeutics, Inc. compare | $127.3M |
| RYTM Rhythm Pharmaceuticals, Inc. | $106.1M |
| CORT Corcept Therapeutics Incorporated compare | $5.0M |
| PRAX Praxis Precision Medicines, Inc. compare | $2.8M |
| ABVX Abivax SA Sponsored ADR compare | $1.4M |
| ORKA Oruka Therapeutics, Inc. compare | $301.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement